Chemical genomics technology has been steadily improving, delivering new biological probes and drugs, and the explicit use of the term 'chemical proteomics' has increased with it, as proteins have always been at the heart of this technology. In "Chemical Genomics and Proteomics: Reviews and Protocols," experts in the field present updated reviews of the chemistry of small molecules and their interaction with protein targets as well as detailed protocols that cover different types of ligands, carbohydrates, and lipids. For example, the generation of their protein targets and methods for measuring their interactions is covered. Written in the highly successful "Methods in Molecular Biology " series format, methodology chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls.

Thorough and up to date, "Chemical Genomics and Proteomics: Reviews and Protocols" aims to provide inspiration to those who wish to use chemical genomics and proteomics in their work and develop this young field into full maturity through the incorporation of the new biological and chemical technologies beginning to emerge here."

The Science and Business of Drug Discovery is written for those who want to learn about the biopharmaceutical industry and its products whatever their level of technical knowledge. Its aim is to demystify the jargon used in drug development, but in a way that avoids over simplification and the resulting loss of key information. Each of the twenty chapters is illustrated with figures and tables which clarify some of the more technical points being made. Also included is a drug discovery case history which draws the relevant material together into a single chapter. In recognizing that it is difficult to navigate through the many external resources dealing with drug development, the book has been written to guide the reader towards the most appropriate information sources, including those listed in the two appendices. The following topics are covered: Different types of drugs: from small molecules to stem cells Background to chemistry of small and large molecules Historical background to drug discovery, pharmacology and biotechnology The drug discovery pipeline: from target discovery to marketed medicine Commercial aspects of drug discovery Challenges to the biopharmaceutical industry and its responses Material of specific interest to technology transfer executives, recruiters and pharmaceutical translators

Chemical genomics is an exciting new field that aims to transform biolo- cal chemistry into a high-throughput industrialized process, much in the same way that molecular biology has been transformed by genomics. The inter- tion of small organic molecules with biological systems (mostly proteins) underpins drug discovery in the pharmaceutical and biotechnology industries, and therefore a volume of laboratory protocols that covers the key aspects of chemical genomics would be of use to biologists and chemists in these orga- zations. Academic scientists have been exploring the functions of proteins using small molecules as probes for many years and therefore would also b- efit from sharing ideas and laboratory procedures. Whatever the organizational backgrounds of the scientists involved, the challenges of extracting the ma- mum human benefit from genome sequencing projects remains considerable, and one where it is increasingly recognized that chemical genomics will play an important part. Chemical Genomics: Reviews and Protocols is divided into two sections, the first being a series of reviews to describe what chemical genomics is about and to set the scene for the protocol chapters. The subject is introduced by Paul Caron, who explains the various flavors of chemical genomics. This is f- lowed by Lutz Weber and Philip Dean who cover the interaction between organic molecules and protein targets from the different perspectives of la- ratory experimentation and in silico design. The protocols begin with the me- ods developed in Christopher Lowes' laboratory (Roque et al.

"The Science and Business of Drug Discovery" is written for those who want to learn about the biopharmaceutical industry and its products whatever their level of technical knowledge. Its aim is to demystify the jargon used in drug development, but in a way that avoids over simplification and the resulting loss of key information. Each of the nineteen chapters is illustrated with figures and tables which clarify some of the more technical points being made. Also included is a drug discovery case history which draws the relevant material together into a single chapter. In recognizing that it is difficult to navigate through the many external resources dealing with drug development, the book has been written to guide the reader towards the most appropriate information sources, including those listed in the two appendices.

The following topics are covered: Different types of drugs: from small molecules to stem cellsBackground to chemistry of small and large moleculesHistorical background to drug discovery, pharmacology and biotechnologyThe drug discovery pipeline: from target discovery to marketed medicineCommercial aspects of drug discoveryChallenges to the biopharmaceutical industry and its responses Material of specific interest to technology transfer executives, recruiters and pharmaceutical translators.

Chemical genomics technology has been steadily improving, delivering new biological probes and drugs, and the explicit use of the term 'chemical proteomics' has increased with it, as proteins have always been at the heart of this technology. In Chemical Genomics and Proteomics: Reviews and Protocols, experts in the field present updated reviews of the chemistry of small molecules and their interaction with protein targets as well as detailed protocols that cover different types of ligands, carbohydrates, and lipids. For example, the generation of their protein targets and methods for measuring their interactions is covered. Written in the highly successful Methods in Molecular Biology (TM) series format, methodology chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Thorough and up to date, Chemical Genomics and Proteomics: Reviews and Protocols aims to provide inspiration to those who wish to use chemical genomics and proteomics in their work and develop this young field into full maturity through the incorporation of the new biological and chemical technologies beginning to emerge here.

The Science and Business of Drug Discovery is written for those who want to learn about the biopharmaceutical industry and its products whatever their level of technical knowledge. Its aim is to demystify the jargon used in drug development, but in a way that avoids over simplification and the resulting loss of key information. Each of the nineteen chapters is illustrated with figures and tables which clarify some of the more technical points being made. Also included is a drug discovery case history which draws the relevant material together into a single chapter. In recognizing that it is difficult to navigate through the many external resources dealing with drug development, the book has been written to guide the reader towards the most appropriate information sources, including those listed in the two appendices. The following topics are covered: Different types of drugs: from small molecules to stem cells Background to chemistry of small and large molecules Historical background to drug discovery, pharmacology and biotechnology The drug discovery pipeline: from target discovery to marketed medicine Commercial aspects of drug discovery Challenges to the biopharmaceutical industry and its responses Material of specific interest to technology transfer executives, recruiters and pharmaceutical translators.

Chemical genomics is an exciting new field that aims to transform biolo- cal chemistry into a high-throughput industrialized process, much in the same way that molecular biology has been transformed by genomics. The inter- tion of small organic molecules with biological systems (mostly proteins) underpins drug discovery in the pharmaceutical and biotechnology industries, and therefore a volume of laboratory protocols that covers the key aspects of chemical genomics would be of use to biologists and chemists in these orga- zations. Academic scientists have been exploring the functions of proteins using small molecules as probes for many years and therefore would also b- efit from sharing ideas and laboratory procedures. Whatever the organizational backgrounds of the scientists involved, the challenges of extracting the ma- mum human benefit from genome sequencing projects remains considerable, and one where it is increasingly recognized that chemical genomics will play an important part. Chemical Genomics: Reviews and Protocols is divided into two sections, the first being a series of reviews to describe what chemical genomics is about and to set the scene for the protocol chapters. The subject is introduced by Paul Caron, who explains the various flavors of chemical genomics. This is f- lowed by Lutz Weber and Philip Dean who cover the interaction between organic molecules and protein targets from the different perspectives of la- ratory experimentation and in silico design. The protocols begin with the me- ods developed in Christopher Lowes' laboratory (Roque et al.

The Science and Business of Drug Discovery is written for those who want to learn about the biopharmaceutical industry and its products whatever their level of technical knowledge. Its aim is to demystify the jargon used in drug development, but in a way that avoids over simplification and the resulting loss of key information. Each of the twenty chapters is illustrated with figures and tables which clarify some of the more technical points being made. Also included is a drug discovery case history which draws the relevant material together into a single chapter. In recognizing that it is difficult to navigate through the many external resources dealing with drug development, the book has been written to guide the reader towards the most appropriate information sources, including those listed in the two appendices. The following topics are covered: Different types of drugs: from small molecules to stem cells Background to chemistry of small and large molecules Historical background to drug discovery, pharmacology and biotechnology The drug discovery pipeline: from target discovery to marketed medicine Commercial aspects of drug discovery Challenges to the biopharmaceutical industry and its responses Material of specific interest to technology transfer executives, recruiters and pharmaceutical translators